No Data
Investors in UroGen Pharma (NASDAQ:URGN) Have Unfortunately Lost 42% Over the Last Five Years
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating
UroGen Announces FDA Acceptance Of Its New Drug Application For UGN-102 For Intravesical Solution
UroGen Announces FDA Acceptance of Its New Drug Application for UGN-102
UroGen Started at Buy by EF Hutton, RTGel Technology Cited
EF Hutton Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $25